COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Quality of Care of Children With Sickle Cell Disease (SCD) Screened at Birth in France (EVADREP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03119922
Recruitment Status : Completed
First Posted : April 19, 2017
Last Update Posted : April 19, 2017
National reference center for thalassemia
National laboratories in charge of the SCD new born screening
Reference and competence centers for RBC disorders
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:

The main objective of this study is to evaluate at the national level (France)

  • the early healthcare practices for children with sickle cell disease screened at birth,
  • the adequacy of theses practices with the national recommendations,
  • their variability over time and according the characteristics of treatment centers.

Will be studied in particular the diffusion of the latest preventive measures (practice of trans-cranial Doppler and pneumococcal conjugate vaccine) and their link with the residual risks of death, stroke and invasive pneumococcal infections. The study includes all patients born in France between 01/01/2006 and 31/12/2010. Events are recorded and analysed only during the first 5 years of life.

Condition or disease Intervention/treatment
New-borns Screening Sickle Cell Disease Other: No intervention

Detailed Description:

In agreement with the National Insurance Fund (CNAMTS) and the French Association for Screening and Prevention of Child Handicaps (AFDPHE), the French SCD newborn screening (NBS) program is not universal but "targeted" to children identified "at risk" because of the geographical origin of their parents (from a country where the prevalence of sickle cell trait is high: Sub-Saharan Africa, the Caribbean, North Africa, Mediterranean Basin). The number of children diagnosed at birth is increasing steadily each year and sickle cell disease is now in France the most common disease found among those screened in the neonatal period. The total number of new-borns diagnosed by NBS from 01/01/2006 to 31/12/2010 is 1800 (AFDPHE data).

In the absence of preventive care, a high mortality rate is observed during the first 5 years of life, the two main causes of death being invasive pneumococcal infection and splenic sequestration acute. Early care allows to largely preventing invasive pneumococcal disease (by combination of PeniV long-term treatment and pneumococcal vaccinations) and severe acute splenic sequestrations (by establishing a parent education program). Also, prevention of cerebral vascular disease, the most serious complications of sickle cell disease in young children, has been made possible the last 10-15 years by the systematic use of trans-cranial Doppler (TCD). In rich countries, the mortality rate of SCD children detected at birth, is now reduced to less than1-2%. The last French report analysed the results of national NBS program for the period 1995- 2000. Consequently these results did not take into account the most recent advances (use of pneumococcal conjugate vaccine and diffusion of TCD). It is now well demonstrated that these two preventive actions have further improved the morbidity and mortality of children with sickle cell disease.

Recently the French paediatric team from Creteil (France), reported the results of 217 children screened at birth between 1988 and 2007: this single-center study finds excellent results with a 1.9% probability of occurrence of stroke at the age of 18 years for SS and S-Beta0 children. These results should be compared with those obtained for the whole concerned population in France. In order to describe and analyse recent national results on residual morbidity and mortality, the investigators conducted this national retrospective study (EVADREP) studying clinical care during the 5 first years of life of SCD patients diagnosed at birth for the period 2006- 2010.

Layout table for study information
Study Type : Observational
Actual Enrollment : 1750 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: National Project for Healthcare Assessment of SCD Children Diagnosed by Newborn Screening in France
Study Start Date : March 2014
Actual Primary Completion Date : December 2015
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
SCD french new born
New-borns diagnosed by NBS from 01/01/2006 to 31/12/2010 (AFDPHE data, France)
Other: No intervention

Primary Outcome Measures :
  1. Survival at 3 years of age [ Time Frame: between 1/01/2014 and 31/12/2015 ]
  2. Probability of survival at 5 years of age [ Time Frame: between 1/01/2014 and 31/12/2015 ]
  3. Causes of death [ Time Frame: between 1/01/2014 and 31/12/2015 ]

Secondary Outcome Measures :
  1. Use of pneumococcal preventive measures: proportion of children who received a full pneumococcal vaccine program (4Prevenar + 1 P23) at 3 and 5 years of age [ Time Frame: between 1/01/2014 and 31/12/2015 ]
  2. National diffusion of Trans-cranial Doppler (TCD) : proportion of children who underwent a least one TCD at the age of 2 years and the proportion of children annually monitored [ Time Frame: between 1/01/2014 and 31/12/2015 ]
  3. Proportion of children lost to follow-up at birth, at 3 and 5 years of age and reasons for the lack of monitoring [ Time Frame: between 1/01/2014 and 31/12/2015 ]
  4. Poportion of patient with current residual risk of stroke and invasive bacterial infections especially pneumococcal infection at 3 years of age [ Time Frame: between 1/01/2014 and 31/12/2015 ]
  5. Number of patient with current residual risk of stroke and invasive bacterial infections especially pneumococcal infection at 5 years of age (probability) [ Time Frame: between 1/01/2014 and 31/12/2015 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   3 Years to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The project is national and aims exhaustiveness of participation of all children diagnosed with major sickle cell syndrome through newborn screening in the period of interest. The choice 2006 - 2010 is justified by the fact that during this recent period, new prevention tools (TCD, Prevenar) were fully available. The upper limit set on 31/12/2010 led for all children to a minimum follow of 3 years,

Inclusion Criteria:

  • Children born in France (metropolitan France and DOM/TOM) between 01/01/2006 and 31/12/2010
  • Identified with a major sickle cell syndrome through national newborn screening .
  • All types of major sickle cell disease are concerned: SS, S-Beta0 or +, SC, other (S-O-Arab, S-D Punjab)

Exclusion Criteria:

  • Refusal to participate in the study expressed by the holders of parental authority
Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris Identifier: NCT03119922    
Other Study ID Numbers: NI 12001
First Posted: April 19, 2017    Key Record Dates
Last Update Posted: April 19, 2017
Last Verified: December 2016
Keywords provided by Assistance Publique - Hôpitaux de Paris:
major sickle cell disease (SCD)
pneumococcal preventive measures
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn